Skip to content
Catalyst

arachidonic acidWhat was measured

Measured, with no finding

473 endpoints

Show what was measuredHide what was measured
  • EGC-3'-O-glucuronide formation catalytic efficiency (Vmax/Km) across tissues

    unclear

    The V(max)/K(m) for (-)-EGC-3'-O-glucuronide followed the following order: mouse liver > human liver > rat liver > rat and mouse small intestine.

    PMID 12642472 · one of two readings recorded this

  • EGCG-4"-O-glucuronide formation catalytic efficiency (Vmax/Km) across tissues

    unclear

    The catalytic efficiency (V(max)/K(m)) for (-)-EGCG-4"-O-glucuronide formation followed the order: mouse intestine > mouse liver > human liver > rat liver >> rat small intestine.

    PMID 12642472 · one of two readings recorded this

  • Release of arachidonic acid from HT-29 cells

    decreases

    Some of these catechin glucuronides retained the activities of their parent compounds in radical scavenging and in inhibiting the release of arachidonic acid from HT-29 human colon cancer cells.

    PMID 12642472 · one of two readings recorded this

  • ARA level versus breast-fed

    no effect

    In contrast, ARA was not significantly lower compared with B in any group in any tissue but was significantly elevated in liver and brain.

    PMID 12736388 · one of two readings recorded this

  • DHA concentration, all tissues

    increases

    The B and P+ groups had significantly higher DHA concentration in all tissues than T- and P-.

    PMID 12736388 · one of two readings recorded this

  • DHA content, brain

    decreases

    The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.

    PMID 12736388 · one of two readings recorded this

  • DHA content, liver

    decreases

    The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.

    PMID 12736388 · one of two readings recorded this

  • DHA content, plasma

    decreases

    The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.

    PMID 12736388 · one of two readings recorded this

  • DHA content, retina

    decreases

    The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.

    PMID 12736388 · one of two readings recorded this

  • RBC/plasma ARA correlation with tissue ARA

    no effect

    RBC and plasma DHA were correlated with DHA in tissues; RBC/plasma ARA were uncorrelated with tissue ARA.

    PMID 12736388 · one of two readings recorded this

  • Brain linoleic acid-derived ARA accretion

    no effect

    Brain linoleic acid-derived ARA accretion was significantly greater in the unsupplemented term group but not in the preterm groups compared with the breast-fed group.

    PMID 14523049 · one of two readings recorded this

  • Brain linoleic acid-derived ARA accretion

    increases

    Brain linoleic acid-derived ARA accretion was significantly greater in the unsupplemented term group but not in the preterm groups compared with the breast-fed group.

    PMID 14523049 · one of two readings recorded this

  • Brain linolenic acid-derived DHA accretion

    increases

    Brain accretion of linolenic acid-derived DHA was approximately 3-fold greater for the formula groups than for the breast-fed group

    PMID 14523049 · one of two readings recorded this

  • DHA level and neurite length per neuron

    decreases

    Furthermore, hippocampal cultures obtained from n-3 fatty acid deficient animals contained a lower DHA level and a neuronal population with shorter neurite length per neuron in comparison to those obtained from animals with adequate n-3 fatty acids.

    PMID 15287904 · one of two readings recorded this

  • Neurite growth

    no effect

    However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.

    PMID 15287904 · one of two readings recorded this

  • Neurite growth

    no effect

    However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.

    PMID 15287904 · one of two readings recorded this

  • Neurite growth

    no effect

    However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.

    PMID 15287904 · one of two readings recorded this

  • Neurite length in deficient cultures

    increases

    DHA supplementation to the deficient group recovered the neurite length to the level similar to n-3 fatty acid adequate cultures.

    PMID 15287904 · one of two readings recorded this

  • neurite length per neuron and branch number in rat embryonic hippocampal primary cultures

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.

    PMID 15287904 · one of two readings recorded this

  • neurite length per neuron and number of branches in rat embryonic hippocampal primary cultures

    no effect, supplementation with arachidonic acid did not have any effect on neurite growth

    Not recorded as a finding: this platform holds no node for the endpoint

    However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.

    PMID 15287904 · one of two readings recorded this

  • Neurite length per neuron and number of branches

    increases

    We found that DHA supplementation in culture increased the population of neurons with longer neurite length per neuron and with higher number of branches.

    PMID 15287904 · one of two readings recorded this

  • birth weight

    Birth weight (g)c | 875 ± 65A | 821 ± 119A | 894 ± 96A | 632 ± 61B | 608 ± 71B

    PMID 15975147 · one of two readings recorded this

  • 22:5n-6 (Osbond acid) concentration, Corpus Callosum

    modulates

    Corpus Callosum | 1.16 ± 0.22 | 1.79 ± 0.26 | 1.43 ± 0.27 | 1.41 ± 0.22 | 1.94 ± 0.33 | T+,P->B; T->T+; T+>P+; P->T-,P+

    PMID 15975147 · one of two readings recorded this

  • 22:5n-6 (Osbond acid) concentration, Hippocampus

    modulates

    Hippocampus | 1.86 ± 0.30 | 2.27 ± 0.40 | 2.28 ± 0.41 | 1.88 ± 0.16 | 2.33 ± 0.14 | T+,T-,P->B; T+,T-,P->P+

    PMID 15975147 · one of two readings recorded this

  • 22:5n-6 (Osbond acid) concentration, Occipital

    modulates

    Occipital | 1.97 ± 0.23 | 2.26 ± 0.32 | 2.47 ± 0.40 | 1.85 ± 0.23 | 2.39 ± 0.16 | T-,P->B; T+,T-,P->P+

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, breastfed versus P- in affected regions

    decreases

    Remarkably, the B group is of lower ARA concentration than the P- group in every case, and this is significant in 7 of 8 regions

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Corpus Collosum

    modulates

    Corpus Collosum | 9.9 ± 0.6 | 11.2 ± 0.5 | 10.2 ± 0.7 | 11.3 ± 0.5 | 11.4 ± 0.9 | [T+,P+,P->B; T+,P+,P->T-]

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Hypothalamus

    modulates

    Hypothalamus | 11.7 ± 0.7 | 12.2 ± 0.6 | 11.4 ± 0.4 | 12.6 ± 0.7 | 12.9 ± 0.5 | [T+,P+,P->T-; P+,P->B]

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Inferior Colliculus

    modulates

    Inferior Colliculus | 9.3 ± 0.5 | 10.5 ± 1.0 | 9.3 ± 0.7 | 10.3 ± 0.5 | 10.3 ± 0.4 | [T+,P+,P->B,T-]

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Lateral Geniculate

    modulates

    Lateral Geniculate | 9.5 ± 1.1 | 10.6 ± 0.6 | 9.9 ± 0.4 | 10.7 ± 0.5 | 10.5 ± 0.4 | [T+,P+,P->B; P+>T-]

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Occipital

    modulates

    Occipital | 13.2 ± 0.8 | 13.3 ± 0.7 | 13.6 ± 0.8 | 14.0 ± 0.5 | 14.3 ± 0.6 | [P->B,T+]

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Optic Tract

    modulates

    Optic Tract | 6.8 ± 0.3 | 6.9 ± 0.4 | 7.2 ± 0.7 | 7.4 ± 0.3 | 7.7 ± 0.4 | [P-,P+>B; P->T+]

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Superior Colliculus

    modulates

    Superior Colliculus | 10.1 ± 0.9 | 11.0 ± 0.8 | 10.6 ± 0.7 | 11.0 ± 0.6 | 11.7 ± 0.6 | [T+,P+,P->B; P->T-]

    PMID 15975147 · one of two readings recorded this

  • ARA concentration, Thalamus DM

    modulates

    Thalamus DM | 10.0 ± 0.5 | 10.3 ± 0.6 | 9.6 ± 0.8 | 10.8 ± 0.6 | 10.7 ± 0.7 | [T+,P+,P->T-; P+>B]

    PMID 15975147 · one of two readings recorded this

  • body weight at euthanasia

    Body weight at euthanasia (g)d | 1152 ± 177 | 1147 ± 113 | 1107 ± 145 | 1071 ± 187 | 1035 ± 220

    PMID 15975147 · one of two readings recorded this

  • brain weight at euthanasia

    Brain weight at euthanasia (g)d | 103 ± 4 | 98 ± 6 | 100 ± 11 | 93 ± 8 | 94 ± 9

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Amygdala

    modulates

    Amygdala | 12.0 ± 0.6 | 11.4 ± 0.6 | 10.8 ± 0.9 | 11.7 ± 0.5 | 9.4 ± 0.4 | [B>T-,P-; T+,T-,P+>P-; P+>T-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Caudate

    modulates

    Caudate | 14.3 ± 1.1 | 13.4 ± 0.8 | 13.0 ± 1.1 | 13.5 ± 0.8 | 11.3 ± 0.4 | [B>T-,P-; T+,T-,P+>P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Cerebellum

    modulates

    Cerebellum | 12.6 ± 0.9 | 11.2 ± 0.7 | 10.6 ± 0.8 | 11.4 ± 0.2 | 7.7 ± 0.6 | [B>all; T+>P-; T-,P+>P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Cingulate

    modulates

    Cingulate | 13.4 ± 0.9 | 11.4 ± 0.7 | 10.7 ± 0.8 | 11.8 ± 0.8 | 9.5 ± 0.9 | [B>all; T+>P-; P+>T-,P-; T->P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Corona Radiation

    modulates

    Corona Radiation | 5.5 ± 0.9 | 5.2 ± 0.9 | 4.4 ± 0.4 | 5.7 ± 0.8 | 4.7 ± 0.7 | [B>T-; P+>T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Corpus Callosum

    modulates

    Corpus Callosum | 7.0 ± 1.3 | 7.9 ± 0.7 | 6.4 ± 0.9 | 8.2 ± 0.7 | 6.3 ± 0.7 | [T+>T-,P-; P+>B,T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Frontal

    modulates

    Frontal | 12.7 ± 0.6 | 11.2 ± 0.8 | 10.6 ± 0.7 | 11.4 ± 0.4 | 8.4 ± 1.0 | [B>all; T+>P+,P-; T->P-; P+>P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Globus Pallidus

    modulates

    Globus Pallidus | 15.8 ± 0.5 | 15.4 ± 0.6 | 12.7 ± 2.3 | 16.6 ± 0.3 | 13.4 ± 1.5 | [B>T-,P-; T+>T-,P-; P+>T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Hippocampus

    modulates

    Hippocampus | 13.0 ± 0.8 | 11.6 ± 0.5 | 10.6 ± 1.5 | 12.6 ± 0.5 | 9.0 ± 0.5 | [B>T+,T-,P-; T+,T-,P+>P-; P+>T-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Hypothalamus

    modulates

    Hypothalamus | 12.0 ± 0.4 | 11.3 ± 0.6 | 11.0 ± 0.7 | 12.0 ± 0.8 | 10.6 ± 0.4 | [B>T-,P-; T+>P-; P+>T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Inferior Colliculus

    modulates

    Inferior Colliculus | 14.4 ± 1.0 | 12.9 ± 1.4 | 13.4 ± 1.3 | 15.0 ± 0.6 | 13.4 ± 0.4 | [B>T+; P+>T+,T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Internal Capsule

    no effect

    Internal Capsule | 6.8 ± 1.0 | 7.0 ± 1.5 | 6.4 ± 0.7 | 7.9 ± 0.9 | 6.3 ± 1.4

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Lateral Geniculate

    modulates

    Lateral Geniculate | 11.2 ± 1.6 | 10.6 ± 0.9 | 9.5 ± 0.8 | 11.7 ± 0.7 | 8.8 ± 1.8 | [B>T-,P-; T+>P-; P+>T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Medial Geniculate

    no effect

    Medial Geniculate | 12.5 ± 1.3 | 12.8 ± 1.1 | 12.2 ± 0.9 | 12.6 ± 1.3 | 11.7 ± 0.8

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Occipital

    modulates

    Occipital | 13.9 ± 1.0 | 11.7 ± 0.9 | 10.7 ± 0.8 | 11.8 ± 0.1 | 8.7 ± 0.6 | [B>all; T+>P+,P-; T->P+,P-; P+>P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Optic Nerve

    modulates

    Optic Nerve | 4.5 ± 0.5 | 4.0 ± 0.9 | 3.9 ± 0.4 | 4.8 ± 0.9 | 3.6 ± 0.3 | [B>T-,P-; T+>P-; P+>all]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Optic Tract

    modulates

    Optic Tract | 4.8 ± 0.5 | 4.5 ± 0.4 | 4.3 ± 0.6 | 5.1 ± 0.3 | 3.9 ± 0.4 | [B,T+>P-; P+>T+,T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Post-Centralis

    modulates

    Post-Centralis | 14.1 ± 0.8 | 12.7 ± 0.8 | 11.7 ± 1.0 | 13.4 ± 0.6 | 10.4 ± 0.2 | [B>T+,T-,P-; T+>T-,P-; P+>T-,P-; T->P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Pre-Centralis

    modulates

    Pre-Centralis | 14.4 ± 0.9 | 12.6 ± 0.6 | 11.7 ± 1.0 | 13.0 ± 0.6 | 10.4 ± 0.7 | [B>all; T+>P-; P+>T-,P-; T->P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Pulvinar

    modulates

    Pulvinar | 13.5 ± 0.6 | 12.7 ± 0.7 | 12.5 ± 1.0 | 14.6 ± 1.1 | 12.0 ± 0.4 | [B>T-,P-; P+>all]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Putamen

    modulates

    Putamen | 14.7 ± 0.8 | 13.9 ± 0.9 | 13.5 ± 0.6 | 13.6 ± 1.3 | 11.6 ± 0.8 | [B>T-,P-; T+,T-,P+>P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Spinal Cord

    no effect

    Spinal Cord1 | 5.7 ± 0.3 | 6.0 ± 1.0 | 5.6 ± 0.5 | 6.2 ± 0.5 | 5.1 ± 0.6

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Superior Colliculus

    modulates

    Superior Colliculus | 15.2 ± 1.2 | 14.2 ± 1.1 | 13.6 ± 0.5 | 15.0 ± 0.4 | 13.4 ± 0.7 | [B>T-,P-; P+>T-,P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Temporal

    modulates

    Temporal | 12.2 ± 0.6 | 10.5 ± 1.1 | 10.3 ± 0.8 | 11.2 ± 0.5 | 9.0 ± 0.7 | [B>all; T+,T-,P+>P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Thalamus DM

    modulates

    Thalamus DM | 13.0 ± 1.0 | 12.4 ± 1.2 | 12.2 ± 0.9 | 13.5 ± 0.8 | 10.9 ± 1.3 | [B>P-; T+,T-,P+>P-]

    PMID 15975147 · one of two readings recorded this

  • DHA concentration, Thalamus VPL

    modulates

    Thalamus VPL | 12.9 ± 0.7 | 12.6 ± 0.9 | 12.2 ± 0.9 | 13.1 ± 1.7 | 10.3 ± 1.6 | [B>P-; T+,T-,P+>P-]

    PMID 15975147 · one of two readings recorded this

  • effect of supplementation on CNS ARA concentrations

    no effect

    The trends for ARA are very different from those for DHA. As noted, treatments were ineffective at altering ARA concentrations in 18 regions

    PMID 15975147 · one of two readings recorded this

  • highest regional CNS ARA concentration (amygdala)

    ARA concentrations range from a high of 13.7 ± 0.5% in the amygdala to a low of 6.8 ± 0.4% in the optic tract

    PMID 15975147 · one of two readings recorded this

  • highest regional CNS DHA concentration (globus pallidus)

    The globus pallidus has the highest DHA concentration at 15.8 ± 0.5% (w/w), while the optic nerve is lowest at 4.5 ± 0.4%

    PMID 15975147 · one of two readings recorded this

  • lowest regional CNS ARA concentration (optic tract)

    ARA concentrations range from a high of 13.7 ± 0.5% in the amygdala to a low of 6.8 ± 0.4% in the optic tract

    PMID 15975147 · one of two readings recorded this

  • lowest regional CNS DHA concentration (optic nerve)

    The globus pallidus has the highest DHA concentration at 15.8 ± 0.5% (w/w), while the optic nerve is lowest at 4.5 ± 0.4%

    PMID 15975147 · one of two readings recorded this

  • Osbond acid (22:5n-6) elevation without dietary DHA

    increases

    In 25 of 26 CNS regions (except thalamus DM), P- was significantly elevated, while T- was significantly elevated in 22 of 26 regions

    PMID 15975147 · one of two readings recorded this

  • stearic acid and adrenic acid (22:4n-6) variation with treatment

    no effect

    Neither 18:0 (stearic acid) nor 22:4n-6 (adrenic acid) showed any statistically significant variation as a function of treatment in these regions

    PMID 15975147 · one of two readings recorded this

  • epididymosomal membrane rigidity (anisotropy)

    increases

    Measures of epididymosomal membrane anisotropy revealed that epididymosomes became more rigid during epididymal transit

    PMID 16510839 · one of two readings recorded this

  • epididymosome cholesterol:phospholipid ratio

    increases

    The cholesterol:phospholipid ratio increased from 0.26 in the caput to 0.48 in the cauda epididymidis

    PMID 16510839 · one of two readings recorded this

  • epididymosome cholesterol:phospholipid ratio

    increases

    The cholesterol:phospholipid ratio increased from 0.26 in the caput to 0.48 in the cauda epididymidis

    PMID 16510839 · one of two readings recorded this

  • epididymosome sphingomyelin and arachidonic acid content

    found that epididymosomes were particularly rich in sphingomyelin (SM) and arachidonic acid

    PMID 16510839 · one of two readings recorded this

  • epididymosome sphingomyelin proportion during epididymal transit

    increases

    The proportion of SM increased markedly during epididymal transit and represented half the total phospholipids in cauda epididymidal epididymosomes

    PMID 16510839 · one of two readings recorded this

  • spermatozoal cholesterol:phospholipid ratio

    no effect

    Epididymal spermatozoa had a constant cholesterol:phospholipid ratio (average, 0.30) during epididymal transit

    PMID 16510839 · one of two readings recorded this

  • spermatozoal sphingomyelin and polyunsaturated fatty acids (arachidonic, docosapentanoic, docosahexanoic acids)

    increases

    Both SM and PUFA increased throughout the epididymal tract

    PMID 16510839 · one of two readings recorded this

  • syntaxin 3 activation by dietary omega-3 linolenic and docosahexaenoic acids relative to arachidonic acid

    increases

    By using syntaxin 3 in a screening assay, we determined that the dietary omega-3 linolenic and docosahexaenoic acids can efficiently substitute for arachidonic acid in activating syntaxin 3

    PMID 16598260 · one of two readings recorded this

  • syntaxin 3 activation

    increases

    Here we show that syntaxin 3 (STX3), a plasma membrane protein, has an important role in the growth of neurites, and also serves as a direct target for omega-6 arachidonic acid

    PMID 16598260 · one of two readings recorded this

  • 15d-PGJ2 formation

    increases

    Stimulation by LPS of selenium-supplemented macrophages resulted in a time-dependent increase in 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) formation, an endogenous inhibitor of IKKbeta activity.

    PMID 17439952 · one of two readings recorded this

  • 15d-PGJ2 synthesis dependence on COX-1 versus COX-2

    increases

    Experiments using specific cyclooxygenase (COX) inhibitors and genetic knockdown approaches indicated that COX-1, and not the COX-2 pathway, was responsible for the increased synthesis of 15d-PGJ2 in selenium-supplemented macrophages.

    PMID 17439952 · one of two readings recorded this

  • IKKbeta activity

    decreases

    In vitro kinase assays revealed that selenium supplementation decreased the activity of IKKbeta in lipopolysaccharide (LPS)-treated macrophages.

    PMID 17439952 · one of two readings recorded this

  • association of erythrocyte ARA with adipose ARA

    increases, p = 0.001

    erythrocyte ARA correlated with adipose ARA (r(2) = 0.470; P < 0.001)

    PMID 17709441 · one of two readings recorded this

  • association of plasma and erythrocyte ARA with neural ARA

    no effect

    Plasma and erythrocyte ARA did not correlate with neural ARA

    PMID 17709441 · one of two readings recorded this

  • association of plasma and erythrocyte DHA with neural and visceral tissue DHA

    increases, p = 0.001

    Plasma and erythrocyte DHA were positively associated with DHA in neural (brain and retina) and visceral (liver and adipose) tissues (r(2) = 0.11-0.56; P < 0.001-P = 0.042)

    PMID 17709441 · one of two readings recorded this

  • association of plasma ARA with adipose ARA

    increases, p = 0.001

    adipose ARA (r(2) = 0.867; P < 0.001)

    PMID 17709441 · one of two readings recorded this

  • association of plasma ARA with liver ARA

    increases, p = 0.02

    Only plasma ARA was associated with liver ARA (r(2) = 0.222; P = 0.02)

    PMID 17709441 · one of two readings recorded this

  • brain and retina ARA

    no effect

    brain and retina ARA was, however, unresponsive to dietary DHA and ARA

    PMID 17709441 · one of two readings recorded this

  • tissue ARA in liver, adipose tissue, plasma, erythrocytes

    increases, p = 0.05

    Tissue ARA (1.1- to 6.0-fold of Diet 0) responded to dietary ARA in liver, adipose tissue, plasma, and erythrocytes (P-trend < 0.05)

    PMID 17709441 · one of two readings recorded this

  • tissue DHA (brain, retina, liver, adipose tissue, plasma, erythrocyte)

    increases, p = 0.01

    Supplementation of dietary DHA and ARA increased DHA in brain, retina, liver, adipose tissue, plasma, and erythrocyte by 1.1- to 25.8-fold of Diet 0 (P-trend < 0.01)

    PMID 17709441 · one of two readings recorded this

  • brain 20:5omega-3 and 22:5omega-3

    no effect

    DHA supplementation effectively increased DHA, but not the intermediate omega-3 fatty acids, 20:5omega-3 and 22:5omega-3

    PMID 18710653 · one of two readings recorded this

  • brain 22:4omega-6 and 22:5omega-6

    increases

    a contemporary diet, high in 18:2omega-6 compromises DHA accretion and leads to increased 22:4omega-6 and 22:5omega-6 in the brain

    PMID 18710653 · one of two readings recorded this

  • brain DHA accretion

    decreases

    a contemporary diet, high in 18:2omega-6 compromises DHA accretion and leads to increased 22:4omega-6 and 22:5omega-6 in the brain

    PMID 18710653 · one of two readings recorded this

  • brain DHA

    increases

    DHA supplementation effectively increased DHA, but not the intermediate omega-3 fatty acids, 20:5omega-3 and 22:5omega-3

    PMID 18710653 · one of two readings recorded this

  • brain DHA

    increases

    an evolutionary diet, low in 18:2omega-6, supports high brain DHA

    PMID 18710653 · one of two readings recorded this

  • neuronal uptake and acylation

    increases

    Using primary cultures of cortical neurons, we show that 22:5omega-6 is efficiently acylated and preferentially taken up over DHA

    PMID 18710653 · one of two readings recorded this

  • secondary neurite growth

    no effect

    However, DHA, but not 22:5omega-6 supports growth of secondary neurites

    PMID 18710653 · one of two readings recorded this

  • secondary neurite growth

    increases

    However, DHA, but not 22:5omega-6 supports growth of secondary neurites

    PMID 18710653 · one of two readings recorded this

  • connexin 40 (gap junction 40) gene expression in aorta

    increases, p = 0.05

    Significant and marked differences were detected for the endothelial nitric oxide synthase (eNOS) gene (1.89-fold, P<0.05) and the connexin 40 (gap junction 40) gene (2.81-fold, P<0.05)

    PMID 19686729 · one of two readings recorded this

  • cyclooxygenase (COX-1) gene expression in aorta

    increases

    Administration of VPP and IPP led to a slight increase in the expression of the cyclooxigenase (COX-1) gene

    PMID 19686729 · one of two readings recorded this

  • endothelial nitric oxide synthase (eNOS) gene expression in aorta

    increases, p = 0.05

    Significant and marked differences were detected for the endothelial nitric oxide synthase (eNOS) gene (1.89-fold, P<0.05) and the connexin 40 (gap junction 40) gene (2.81-fold, P<0.05)

    PMID 19686729 · one of two readings recorded this

  • NF-kappaB subunit gene expression in aorta

    decreases

    a decrease in the expression of both the nuclear factor kappa B subunit (NF-kappaB) gene for vascular function and the peroxisome proliferator activator receptor gamma (PPARgamma) gene

    PMID 19686729 · one of two readings recorded this

  • PPARgamma gene expression in aorta

    decreases

    a decrease in the expression of both the nuclear factor kappa B subunit (NF-kappaB) gene for vascular function and the peroxisome proliferator activator receptor gamma (PPARgamma) gene

    PMID 19686729 · one of two readings recorded this

  • breeding success rate of DHA-supplemented (-/-) males

    no effect

    A breeding success rate of DHA-supplemented (-/-) was comparable to (+/+)

    PMID 19690334 · one of two readings recorded this

  • fertility, sperm count and spermiogenesis of delta-6 desaturase-null males, dietary AA compared with dietary DHA

    Not recorded as a finding: comparator is DHA, an active comparator, not an unsupplemented control; the sentence gives no AA-versus-unsupplemented contrast, and sperm count is reported without a number

    Dietary AA was less effective in restoring fertility, sperm count, and spermiogenesis than DHA.

    PMID 19690334 · one of two readings recorded this

  • fertility, sperm count and spermiogenesis with dietary AA versus DHA

    increases

    Dietary AA was less effective in restoring fertility, sperm count, and spermiogenesis than DHA

    PMID 19690334 · one of two readings recorded this

  • male fertility (breeding success rate), sperm count and spermiogenesis in delta-6 desaturase-null mice fed 0.2% (w/w) AA or DHA diet

    Not recorded as a finding: the comparison was against another active treatment

    Dietary AA was less effective in restoring fertility, sperm count, and spermiogenesis than DHA.

    PMID 19690334 · one of two readings recorded this

  • testis AA level in AA-fed (-/-)

    increases

    In AA-fed (-/-), AA was restored at the (+/+) level, and 22:4n6, an AA elongated product, accumulated in testis

    PMID 19690334 · one of two readings recorded this

  • testis cholesta-3,5-diene

    decreases

    Cholesta-3,5-diene was present in testis of (+/+) and DHA-fed (-/-), whereas it diminished in (-/-) and AA-fed (-/-)

    PMID 19690334 · one of two readings recorded this

  • glucose infusion rate during clamp

    decreases, p = 0.05

    Glucose infusion rates in Wistar rats maintained on a high fat diet (HFD) were significantly lower compared to control rats (22.8 ± 1.3 vs. 31.9 ± 1.4 mg/kg/min; p<0.05)

    PMID 21167181 · one of two readings recorded this

  • glucose infusion rate during clamp

    increases, p = 0.05

    ZA treatment significantly improved (~43%) peripheral tissue insulin sensitivity in HFD fed animals (26.7 ± 1.3 [n=9] vs. 22.8 ± 1.3mg/kg/min; p<0.05)

    PMID 21167181 · one of two readings recorded this

  • hepatic glucose output during clamp

    decreases, p = 0.05

    ZA treatment in high fructose-fed rats showed a significant improvement of hepatic insulin sensitivity compared to non-treatment controls (4.39 vs. 2.18 mg/kg/min; p<0.05)

    PMID 21167181 · one of two readings recorded this

  • hepatic glucose output suppression and glucose infusion rate, hyperinsulinemic euglycemic clamp

    increases, glucose infusion rate 26.7 vs 22.8 mg/kg/min in high-fat-fed rats

    Not recorded as a finding: the intervention held more than the compound

    ZA treatment significantly improved (~43%) peripheral tissue insulin sensitivity in HFD fed animals (26.7 ± 1.3 [n=9] vs. 22.8 ± 1.3mg/kg/min; p<0.05).

    PMID 21167181 · one of two readings recorded this

  • insulin sensitivity by hyperinsulinemic euglycemic clamp (hepatic glucose output suppression; glucose infusion rate)

    increases, ~43% improvement in peripheral tissue insulin sensitivity in HFD-fed rats (26.7 vs 22.8 mg/kg/min)

    Not recorded as a finding: the intervention held more than the compound

    ZA treatment significantly improved (~43%) peripheral tissue insulin sensitivity in HFD fed animals (26.7 ± 1.3 [n=9] vs. 22.8 ± 1.3mg/kg/min; p<0.05).

    PMID 21167181 · one of two readings recorded this

  • suppression of hepatic glucose output by insulin during clamp

    increases, p = 0.05

    High fructose feeding impaired suppression of hepatic glucose output by insulin compared to controls during the clamp procedure (4.39 vs. 2.35 mg/kg/min; p<0.05)

    PMID 21167181 · one of two readings recorded this

  • action potential amplitude, 3xTg-AD versus NonTg

    decreases, p = 0.01

    we observed a decrease in the amplitude of action potentials (P<0.01, Figure 4D), an increase of undershoot voltage variation (P<0.001, Figure 4E) and a reduction of post-spike hyperpolarization (P<0.05, Figure 4F) in 3xTg-AD neurons

    PMID 21383850 · one of two readings recorded this

  • action potential undershoot voltage variation, 3xTg-AD versus NonTg

    increases, p = 0.001

    we observed a decrease in the amplitude of action potentials (P<0.01, Figure 4D), an increase of undershoot voltage variation (P<0.001, Figure 4E) and a reduction of post-spike hyperpolarization (P<0.05, Figure 4F) in 3xTg-AD neurons

    PMID 21383850 · one of two readings recorded this

  • adaptativity ratio, 3xTg-AD

    no effect

    0.27±0.05 (n = 7) for 3xTg-AD mice fed with control diet and 0.22±0.05 (n = 8) for NonTg mice fed with high-DHA diet

    PMID 21383850 · one of two readings recorded this

  • adaptativity ratio, NonTg

    no effect

    was 0.33±0.05 (n = 8) for NonTg mice fed with control diet, 0.35±0.03 (n = 7) for NonTg mice fed with high-DHA diet

    PMID 21383850 · one of two readings recorded this

  • akinetic (low and very low activity) episodes in 3xTg-AD mice

    decreases, p = 0.05

    DHA intake reduced the number of akinetic episodes seen in 3xTg-AD mice (P<0.05, low and very low activity episodes, Figure 2I–J)

    PMID 21383850 · one of two readings recorded this

  • amyloid-beta pathology in cortex

    no effect

    We found no significant effects of DHA on Aβ pathologies

    PMID 21383850 · one of two readings recorded this

  • body weight, 3xTg-AD versus NonTg

    increases, p = 0.001

    As reported previously, 3xTg-AD mice were heavier than NonTg mice (31% for mice fed with control diet and 16% for mice fed with high-DHA diet, P<0.001)

    PMID 21383850 · one of two readings recorded this

  • correlation between cortical AA and DHA concentrations

    decreases, p = 0.001

    we found an inverse relationship between AA and DHA concentrations (r2 = 0.61, P<0.001, data not shown)

    PMID 21383850 · one of two readings recorded this

  • entorhinal neuron cell capacitance, 3xTg-AD versus NonTg

    decreases, p = 0.05

    CC, an indicator of total membrane area, was decreased in neurons from 3xTg-AD mice compared to NonTg (P<0.05; Figure 3A, 3B)

    PMID 21383850 · one of two readings recorded this

  • entorhinal neuron cell capacitance with DHA

    increases, p = 0.05

    DHA treatment prevented this decrease and had an overall increasing effect on CC in all animals (P<0.05)

    PMID 21383850 · one of two readings recorded this

  • F-I curve, 3xTg-AD versus NonTg

    increases, p = 0.001

    we found that the F-I curves were increased in 3xTg-AD mice (P<0.001), but decreased by DHA treatment (P<0.01, Figure 5A–C)

    PMID 21383850 · one of two readings recorded this

  • F-I curve with DHA

    decreases, p = 0.01

    we found that the F-I curves were increased in 3xTg-AD mice (P<0.001), but decreased by DHA treatment (P<0.01, Figure 5A–C)

    PMID 21383850 · one of two readings recorded this

  • first-exposure object exploration time, 3xTg-AD

    no effect

    whereas it was 72±6 (n = 7) and 72±5 (n = 8) for 3xTg-AD mice fed with control or high-DHA diet

    PMID 21383850 · one of two readings recorded this

  • first-exposure object exploration time, NonTg

    increases

    The time spent in seconds to explore the object during the first exposition was 88±3 (n = 8) and 114±3 (n = 8) for NonTg mice fed with control or high-DHA diet

    PMID 21383850 · one of two readings recorded this

  • frontal cortex arachidonic acid (AA) level

    decreases, p = 0.001

    mice fed a high-DHA diet had lower brain levels of AA (−22% for NonTg mice and −25% for 3xTg-AD; P<0.001, Figure 1B)

    PMID 21383850 · one of two readings recorded this

  • frontal cortex arachidonic acid (AA) level

    decreases, p = 0.001

    mice fed a high-DHA diet had lower brain levels of AA (−22% for NonTg mice and −25% for 3xTg-AD; P<0.001, Figure 1B)

    PMID 21383850 · one of two readings recorded this

  • frontal cortex arachidonic acid concentration, gas chromatography, in mice fed a high-DHA diet versus control diet

    decreases, -22% in NonTg mice and -25% in 3xTg-AD mice

    Not recorded as a finding: the compound is what was measured, not what was given

    In parallel, mice fed a high-DHA diet had lower brain levels of AA (−22% for NonTg mice and −25% for 3xTg-AD; P<0.001, Figure 1B) and, therefore, a lower DHA/AA ratio (44% for NonTg and 68% for 3xTg-AD, P<0.001, Table S1).

    PMID 21383850 · one of two readings recorded this

  • frontal cortex DHA/AA ratio

    increases, p = 0.001

    and, therefore, a lower DHA/AA ratio (44% for NonTg and 68% for 3xTg-AD, P<0.001, Table S1)

    PMID 21383850 · one of two readings recorded this

  • frontal cortex DHA/AA ratio

    increases, p = 0.001

    and, therefore, a lower DHA/AA ratio (44% for NonTg and 68% for 3xTg-AD, P<0.001, Table S1)

    PMID 21383850 · one of two readings recorded this

  • frontal cortex DHA level

    increases, p = 0.001

    high DHA consumption induced an increase in frontal cortex DHA of 15% in NonTg mice and of 27% in 3xTg-AD mice, compared to mice fed control diet (P<0.001, Figure 1A and Table S1)

    PMID 21383850 · one of two readings recorded this

  • frontal cortex DHA level

    increases, p = 0.001

    high DHA consumption induced an increase in frontal cortex DHA of 15% in NonTg mice and of 27% in 3xTg-AD mice, compared to mice fed control diet (P<0.001, Figure 1A and Table S1)

    PMID 21383850 · one of two readings recorded this

  • horizontal locomotor activity, 3xTg-AD versus NonTg

    decreases, p = 0.001

    We observed diminished horizontal (P<0.001) and vertical activities (P<0.001) in 3xTg-AD compared to NonTg mice

    PMID 21383850 · one of two readings recorded this

  • hyperpolarization of entorhinal neurons by DHA, NonTg

    decreases, p = 0.001

    DHA consumption led to the hyperpolarization of EC neurons of NonTg mice (P<0.001, Figure 3G)

    PMID 21383850 · one of two readings recorded this

  • novel-object recognition, 3xTg-AD versus NonTg

    decreases, p = 0.05

    3xTg-AD performed significantly worse than NonTg mice (P<0.05)

    PMID 21383850 · one of two readings recorded this

  • novel-object recognition with DHA

    increases, p = 0.05

    the consumption of DHA improved the recognition performance of both NonTg and 3xTg-AD mice (P<0.05)

    PMID 21383850 · one of two readings recorded this

  • post-spike hyperpolarization, 3xTg-AD versus NonTg

    decreases, p = 0.05

    we observed a decrease in the amplitude of action potentials (P<0.01, Figure 4D), an increase of undershoot voltage variation (P<0.001, Figure 4E) and a reduction of post-spike hyperpolarization (P<0.05, Figure 4F) in 3xTg-AD neurons

    PMID 21383850 · one of two readings recorded this

  • resting potential, CC, input resistance and F-I curves after acute DHA

    no effect

    We found that acute application of DHA did not alter the resting potential, CC, input resistance or F-I curves

    PMID 21383850 · one of two readings recorded this

  • resting potential of entorhinal neurons with DHA, NonTg

    decreases

    DHA intake hyperpolarized EC neurons by altering their resting potential from −60 mV to −70 mV, an effect only present in NonTg mice

    PMID 21383850 · one of two readings recorded this

  • rheobase with DHA, NonTg

    increases, p = 0.01

    an increase of rheobase was detected in DHA-enriched neurons from NonTg mice (P<0.01, Figure 5D)

    PMID 21383850 · one of two readings recorded this

  • sEPSC frequency, 3xTg-AD versus NonTg

    increases, p = 0.001

    3xTg-AD neurons displayed more sEPSC than NonTg (<0.001)

    PMID 21383850 · one of two readings recorded this

  • sEPSC frequency with DHA

    increases, p = 0.01

    DHA treatment did not prevent synaptic hyperactivity of EC neurons, but rather increased the frequency of sEPSC in all animals (<0.01)

    PMID 21383850 · one of two readings recorded this

  • soluble phosphorylated tau in cortex

    decreases, p = 0.05

    DHA intake selectively decreased phosphorylated tau (ptau) in TBS fractions (P<0.05, Figure 1D-F, Table S2)

    PMID 21383850 · one of two readings recorded this

  • synaptophysin and PSD95 with DHA

    no effect

    DHA intake had no effect on both pre- and postsynaptic markers

    PMID 21383850 · one of two readings recorded this

  • vertical locomotor activity, 3xTg-AD versus NonTg

    decreases, p = 0.001

    We observed diminished horizontal (P<0.001) and vertical activities (P<0.001) in 3xTg-AD compared to NonTg mice

    PMID 21383850 · one of two readings recorded this

  • hip fracture risk and intakes of EPA, DHA, EPA+DHA and fish

    no effect

    No significant associations were observed among intakes of EPA, DHA, EPA+DHA, or fish

    PMID 21508210 · one of two readings recorded this

  • hip fracture risk, Q4 vs Q1 of AA intake

    decreases

    Men in the highest quartile of AA intake had an 80% lower risk of hip fracture than those in the lowest quartile (Q4 vs. Q1: HR = 0.20; 95% CI = 0.04-0.96)

    PMID 21508210 · one of two readings recorded this

  • hip fracture risk, Q4 vs Q1 of ALA intake

    decreases

    Participants in the highest quartile of ALA intake had a 54% lower risk of hip fracture than those in the lowest quartile (Q4 vs. Q1: HR = 0.46; 95% CI = 0.26-0.83)

    PMID 21508210 · one of two readings recorded this

  • hip fracture risk, trend across quartiles of AA intake

    decreases, p = 0.05

    Protective associations were observed between intakes of ALA (P-trend = 0.02) and hip fracture risk in a combined sample of women and men and between intakes of AA (P-trend = 0.05) and hip fracture risk in men only

    PMID 21508210 · one of two readings recorded this

  • hip fracture risk, trend across quartiles of ALA intake

    decreases, p = 0.02

    Protective associations were observed between intakes of ALA (P-trend = 0.02) and hip fracture risk in a combined sample of women and men and between intakes of AA (P-trend = 0.05) and hip fracture risk in men only

    PMID 21508210 · one of two readings recorded this

  • incident hip fracture by quartile of energy-adjusted dietary arachidonic acid intake, Framingham Osteoporosis Study; arachidonic acid association found in men only. Reason is that the exposure is habitual dietary intake nobody was given, not a supplement, enriched oil or formula

    decreases, Q4 vs Q1 HR 0.20 (95% CI 0.04-0.96), men only

    Not recorded as a finding: another reason, stated per paper

    Men in the highest quartile of AA intake had an 80% lower risk of hip fracture than those in the lowest quartile (Q4 vs. Q1: HR = 0.20; 95% CI = 0.04-0.96).

    PMID 21508210 · one of two readings recorded this

  • chronic lung disease (CLD) odds per 1 mol% reduction in DHA

    increases

    For every 1 mol% reduction in whole blood DHA levels, there was a 2.5-fold increase in the odds of developing CLD (CI 1.3 – 5.0)

    PMID 21658712 · one of two readings recorded this

  • CLD association with AA level

    no effect

    LA and AA birth and follow-up levels were not associated with the development of CLD

    PMID 21658712 · one of two readings recorded this

  • CLD association with DHA, significance after adjustment

    increases, p = 0.001

    remained significant even after adjustment for gestational age, intrauterine growth restriction, severity of illness at birth, sex, and total fat intake during the first postnatal week (p=0.001)

    PMID 21658712 · one of two readings recorded this

  • CLD association with LA:DHA, AA:DHA and n-6:n-3 ratios

    increases

    Increased LA:DHA, AA:DHA and n-6:n-3 ratios were associated with CLD although the large confidence intervals for the latter two limit their interpretability

    PMID 21658712 · one of two readings recorded this

  • CLD association with LA level

    no effect

    LA and AA birth and follow-up levels were not associated with the development of CLD

    PMID 21658712 · one of two readings recorded this

  • CLD prevalence

    ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%

    PMID 21658712 · one of two readings recorded this

  • DHA level in early-onset sepsis

    no effect, n = 2

    No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)

    PMID 21658712 · one of two readings recorded this

  • DHA level in intraventricular hemorrhage

    no effect, n = 31

    No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)

    PMID 21658712 · one of two readings recorded this

  • DHA level in necrotizing enterocolitis

    no effect, n = 5

    No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)

    PMID 21658712 · one of two readings recorded this

  • DHA level in periventricular leukomalacia

    no effect, n = 3

    No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)

    PMID 21658712 · one of two readings recorded this

  • intraventricular hemorrhage prevalence

    ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%

    PMID 21658712 · one of two readings recorded this

  • late-onset sepsis association with LA:DHA ratio

    increases, p = 0.007

    An increased LA:DHA ratio was associated with late-onset sepsis (p=0.007)

    PMID 21658712 · one of two readings recorded this

  • late-onset sepsis hazard per unit decrease in DHA

    unclear

    For every unit decrease in DHA mol% at a given time, there was a 1.4-fold increase in the risk of late-onset sepsis (CI 1.0 – 2.0), though this did not meet statistical significance

    PMID 21658712 · one of two readings recorded this

  • late-onset sepsis hazard with higher LA level

    increases, p = 0.02

    lower AA levels and higher LA levels were significantly associated with the development of late-onset sepsis with a hazard ratio of 1.4 (CI 1.1 – 1.7; p=0.02) and 1.3 (CI 1.04 – 1.4; p=0.02), respectively

    PMID 21658712 · one of two readings recorded this

  • late-onset sepsis hazard with lower AA level

    increases, p = 0.02

    lower AA levels and higher LA levels were significantly associated with the development of late-onset sepsis with a hazard ratio of 1.4 (CI 1.1 – 1.7; p=0.02) and 1.3 (CI 1.04 – 1.4; p=0.02), respectively

    PMID 21658712 · one of two readings recorded this

  • late-onset sepsis incidence

    n = 88

    Late-onset sepsis occurred in 16 of 88 (18%) infants

    PMID 21658712 · one of two readings recorded this

  • mortality

    The mortality rate for the entire cohort was 11% (Table I)

    PMID 21658712 · one of two readings recorded this

  • necrotizing enterocolitis prevalence

    ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%

    PMID 21658712 · one of two readings recorded this

  • periventricular leukomalacia prevalence

    ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%

    PMID 21658712 · one of two readings recorded this

  • retinopathy of prematurity (ROP) association with DHA level

    no effect

    no significant association between DHA levels nor in AA and LA levels in the follow-up period were associated with the development of ROP

    PMID 21658712 · one of two readings recorded this

  • ROP association with AA level

    no effect

    no significant association between DHA levels nor in AA and LA levels in the follow-up period were associated with the development of ROP

    PMID 21658712 · one of two readings recorded this

  • ROP association with LA:DHA, AA:DHA and n-6:n-3 ratios

    no effect

    none of the three ratios was associated with ROP

    PMID 21658712 · one of two readings recorded this

  • ROP association with LA level

    no effect

    no significant association between DHA levels nor in AA and LA levels in the follow-up period were associated with the development of ROP

    PMID 21658712 · one of two readings recorded this

  • ROP prevalence

    ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%

    PMID 21658712 · one of two readings recorded this

  • sepsis (early or late) prevalence

    ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%

    PMID 21658712 · one of two readings recorded this

  • whole blood 22:5n-3 fold change from birth

    increases

    In the n-3 pathway, there was an increase in 20:5n-3 (EPA) and 22:5n-3 compared with birth levels, 1.7 and 1.5-fold respectively; but a decrease in the downstream product, 22:6n-3 (DHA) by 1.6-fold

    PMID 21658712 · one of two readings recorded this

  • whole blood AA level

    At birth, the mean mol% ± SE (standard error) for LA was 7.0 ± 0.2, 17.2 ± 0.2 for AA, and 6.9 ± 0.2 for DHA

    PMID 21658712 · one of two readings recorded this

  • whole blood AA level

    decreases

    AA levels declined by 30% from 17.2 mol% at birth to 11.8 mol% at week 1 and remained constant at 11.4 to 11.6 mol% for the remaining three postnatal weeks

    PMID 21658712 · one of two readings recorded this

  • whole blood ALA (18:3n-3) fold change from birth

    increases

    by 19.2 and 1.1-fold, respectively

    PMID 21658712 · one of two readings recorded this

  • whole blood DHA (22:6n-3) fold change from birth

    decreases

    In the n-3 pathway, there was an increase in 20:5n-3 (EPA) and 22:5n-3 compared with birth levels, 1.7 and 1.5-fold respectively; but a decrease in the downstream product, 22:6n-3 (DHA) by 1.6-fold

    PMID 21658712 · one of two readings recorded this

  • whole blood DHA level

    At birth, the mean mol% ± SE (standard error) for LA was 7.0 ± 0.2, 17.2 ± 0.2 for AA, and 6.9 ± 0.2 for DHA

    PMID 21658712 · one of two readings recorded this

  • whole blood DHA level

    decreases

    The mean DHA level fell by approximately 40% from 6.9 mol% at birth to 4.4 mol% at week 1, and subsequently remained steady at 4.0 to 4.2 mol% for the remainder of the postnatal period

    PMID 21658712 · one of two readings recorded this

  • whole blood EPA (20:5n-3) fold change from birth

    increases

    In the n-3 pathway, there was an increase in 20:5n-3 (EPA) and 22:5n-3 compared with birth levels, 1.7 and 1.5-fold respectively; but a decrease in the downstream product, 22:6n-3 (DHA) by 1.6-fold

    PMID 21658712 · one of two readings recorded this

  • whole blood LA (18:2n-6) fold change from birth

    increases

    In addition to a 2.7-fold increase in the essential fatty acid 18:2n-6 (LA)

    PMID 21658712 · one of two readings recorded this

  • whole blood LA level

    At birth, the mean mol% ± SE (standard error) for LA was 7.0 ± 0.2, 17.2 ± 0.2 for AA, and 6.9 ± 0.2 for DHA

    PMID 21658712 · one of two readings recorded this

  • whole blood LA level

    increases

    The mean LA level increased from 7.0 mol% at birth to 18.8 mol% at week 1 and remained level over the subsequent 4 weeks

    PMID 21658712 · one of two readings recorded this

  • whole blood oleic acid (18:1n-9) fold change from birth

    increases

    by 19.2 and 1.1-fold, respectively

    PMID 21658712 · one of two readings recorded this

  • 16:1 and 18:1 CE molecular species

    increases

    In particular, the Western diet led to large increases in both 16:1 and 18:1 CE molecular species

    PMID 21904795 · one of two readings recorded this

  • 18:1 CE

    decreases

    With both fatty acid supplementations to the cell culture media the respective CE molecular species increased with an accompanied decrease in the amount of 18:1 CE

    PMID 21904795 · one of two readings recorded this

  • 18:2 CE

    increases

    Figure 4, Panel B demonstrates that J774 cells supplemented with linoleic acid in the media have increased levels of intracellular 18:2 CE (m/z 671.73)

    PMID 21904795 · one of two readings recorded this

  • 22:4 and 24:4 CE molecular species (elongation of 20:4)

    increases

    Studies with arachidonic acid supplementation of J774 cells unexpectedly revealed that arachidonic acid addition led to an increase in elongated CE molecular species, which were observed in the CE pool

    PMID 21904795 · one of two readings recorded this

  • air oxidation of 18:0 CE

    no effect

    NL 368.5 scans of 18:0 CE exposed to ambient air for 15 h indicated that this saturated molecular species was not degraded in an oxidizing environment

    PMID 21904795 · one of two readings recorded this

  • air oxidation of polyunsaturated CE (18:2, 20:4, 22:6)

    increases

    In contrast, 18:2, 20:4 and 22:6 CE molecular species were significantly oxidized after exposure to ambient air for 15 h

    PMID 21904795 · one of two readings recorded this

  • arachidonic acid incorporation into CE pool (20:4 CE)

    increases

    Interestingly, as shown in Figure 4 (Panel C), J774 cells incorporate arachidonic acid into CE pools (m/z 695.72)

    PMID 21904795 · one of two readings recorded this

  • basal CE composition (18:1 CE predominant)

    unclear

    The mass spectra using NL 368.5 for cells without fatty acid treatment revealed that 18:1 CE (m/z 673.73) was predominantly present in J774 cells grown in the cell culture media with minimal levels of 18:2 and 20:4 CE present in these cells

    PMID 21904795 · one of two readings recorded this

  • total CE

    no effect

    The total CE levels only marginally changed in cells treated with fatty acids due to the accumulation of new molecular species being offset by the decrease in 18:1 CE levels

    PMID 21904795 · one of two readings recorded this

The whole record — 473 rows